Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

Frontiers in Pharmacology(2022)10.3389/fphar.2022.894535Source: DataRank Database

Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells is a research paper published in Frontiers in Pharmacology (2022). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.33)OA: goldTopics (33)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Omar S. Al‐Odat,Robert Chitren,J Singh ORCID,Sandeep Kumar Srivastava ORCID,Krishne Gowda ORCID

Live enrichment

PubMed:36160379 PMC:PMC9500300 OpenAlex:https://openalex.org/W4295182927

NCI NIH HHS

Grant: R01 CA241148

National Institutes of Health

Grant: 5R35ES028244-08

Activation of the Ah receptor and epithelial integrity

National Institutes of Health

Grant: 5R01CA241148-04

Targeting Aldehyde Dehydrogenase for Cancer Prevention

FWCI

1.33

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

goldLicense: cc-by

journalhttps://doi.org/10.3389/fphar.2022.894535

publisherhttps://doi.org/10.3389/fphar.2022.894535

publisherhttps://www.frontiersin.org/articles/10.3389/fphar.2022.894535/full

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36160379

repositoryhttps://doaj.org/article/6aace12e025c4c0bab03f2c7841776cc

Fields of Study

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia ResearchPI3K/AKT/mTOR signaling in cancer0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

Bruton's tyrosine kinaseIbrutinibBortezomibCancer researchStem cellTyrosine kinasePopulationCancer stem cellPharmacologyChemistryMultiple myelomaMedicineBiologyImmunologyLeukemiaSignal transductionCell biologyChronic lymphocytic leukemiaBiochemistryHematological malignanciesBruton’s Tyrosine KinaseBtk InhibitorAcquired MutationMultiple Myeloma Stem Cell-like CellsRM1-950Pharmacology (medical)Therapeutics. Pharmacology

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

FAIR Checklist

Authors (12)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)